Takeda Wins Japan Approval for ORZEYFUL in Narcolepsy
OSAKA, Japan & CAMBRIDGE, Massachusetts, Aug 24, 2026 Takeda Pharmaceutical Company Limited announced that Japan’s Ministry of Health, Labour...
neuroscience
Advertisement
Alkermes Publishes Alixorexton Phase 2 Narcolepsy Data
DUBLIN, August 24, 2026 Alkermes plc announced the publication of positive Vibrance-1 Phase 2 results for alixorexton in The...
Teva’s Ecopipam NDA Wins FDA Priority Review
PARSIPPANY, N.J., August 19, 2026 Teva Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted its...
AlzeCure Receives $10M Upfront Payment From Lilly
Stockholm, Sweden, August 18, 2026 AlzeCure Pharma AB has received the full $10 million upfront payment from Eli Lilly...
Leal Therapeutics Advances LTX-001 in Schizophrenia Trial
Worcester, Massachusetts, August 17, 2026 Leal Therapeutics, a clinical-stage biopharmaceutical company developing neuro-metabolic therapeutics for central nervous system disorders,...
Advertisements
Helus Pharma Completes Phase 3 HLP003 Enrollment in MDD
NEW YORK and TORONTO, Aug. 14, 2026 Helus Pharma is advancing its late-stage clinical development strategy for novel serotonergic...
AC Immune Receives FDA Fast Track Designation for ACI-7104 in Parkinson’s
LAUSANNE, Switzerland, August 11, 2026 AC Immune SA announced that the U.S. Food and Drug Administration (FDA) has granted...
Vistagen Reports Positive Phase 2 Fasedienol Repeat-Dose Data
SOUTH SAN FRANCISCO, Calif., August 6, 2026 Vistagen announced positive topline results from its exploratory Phase 2 repeat-dose clinical...
Lunai Bioworks Expands Parkinson’s AI Drug Discovery Alliance
Sacramento & San Diego, California, August 4, 2026 Lunai Bioworks Inc. has announced a definitive Master Collaboration Agreement with...
Ceribell Secures CMS NTAP for Delirium Monitor System
SUNNYVALE, Calif., Aug. 3, 2026 Ceribell, Inc. has secured a significant reimbursement milestone after the U.S. Centers for Medicare...
Advertisement
